There are no well-defined treatment recommendations for elderly patients with advanced head and neck squamous cell carcinoma. This study aimed to investigate whether aggressive treatment among the elderly translated into better survival outcomes.
Study Design
Retrospective cohort study.
Setting
Single tertiary institution.
Subjects and Methods
Elderly patients (≥60 years) with advanced-stage head and neck squamous cell carcinoma (stage III and IV) treated between January 1991 and May 2014 were reviewed. According to current National Comprehensive Cancer Network guidelines, they were classified to have received standard or substandard treatment. Overall survival (OS), locoregional recurrence-free survival, and distant recurrence-free survival were evaluated.
Results
A total of 355 patients were treated curatively: 194 with up-front surgery and 161 with radiotherapy or concurrent chemotherapy and radiotherapy. Median OS was higher among patients who received standard treatment (42.0 vs 16.0 months, P < .001). On multivariate analysis, standard treatment showed superior OS (P < .001). Use of substandard treatment showed a hazard ratio of 2.09 (95% CI, 1.59-2.74) for poorer OS.
Conclusion
Aggressive standard treatment protocols should be advocated for elderly patients, where comorbidities permit, as they confer better outcomes.
MarurSForastiereAA.Head and neck cancer: changing epidemiology, diagnosis and treatment. Mayo Clin Proc. 2008;83:489-501.
5.
PignonJPle MaitreAMaillardEBourhisJ; on behalf of the MACH-NC Collaborative Group. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17346 patients. Radiother Oncol. 2009;92:4-14.
6.
BernierJDomengeCOzsahinMet al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer: European Organization for Research and Treatment of Cancer Trial 22931. N Engl J Med. 2004;350:1945-1952.
7.
CooperJSPajakTFForastiereAAet al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck: Radiation Therapy Oncology Group 9501. N Engl J Med. 2004;350:1937-1944.
8.
AminMBEdgeSBGreeneFLet al. AJCC Cancer Staging Manual. 8th ed.New York, NY: Springer; 2017.
9.
Department of Veterans Affairs Laryngeal Cancer Study Group, WolfGTFisherSGet al. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med. 1991;324:1685-1690.
10.
IyerNGTanDSTanVKet al. Randomized trial comparing surgery and adjuvant radiotherapy versus concurrent chemoradiotherapy in patients with advanced, nonmetastatic squamous cell carcinoma of the head and neck: 10-year update and subset analysis [erratum in Cancer. 2015;121:3560]. Cancer. 2015;121:1599-1607.
11.
D’CruzAKVaishRKapreNet al; Head and Neck Disease Management Group. Elective versus therapeutic neck dissection in node-negative oral cancer. N Engl J Med. 2015;373:521-529.
12.
BonnerJAHarariPMGiraltJet al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. 2010;11:21-28.
13.
WirthLJ.Cetuximab in human papillomavirus–positive oropharynx carcinoma. J Clin Oncol. 2016;34:1289-1291.
SikoraAGTonioloPDeLacureMD.The changing demographics of head and neck squamous cell carcinoma in the United States. Laryngoscope. 2004;114:1915-1923.
17.
de RijkeJMSchoutenLJSchoutenHCet al. Age-specific differences in the diagnostics and treatment of cancer patients aged 50 years and older in the province of Limburg, the Netherlands. Ann Oncol. 1996;7:677-685.
18.
FentimanISTirelliUMonfardiniSet al. Cancer in the elderly: why so badly treated?Lancet. 1990;335:1020-1022.
19.
JuarezJEChoiJSt JohnMet al. Patterns of care for elderly patients with locally advanced head and neck cancer. Int J Radiat Oncol Biol Phys. 2017;98:767-774.
20.
VanderWaldeNAFlemingMWeissJCheraBS.Treatment of older patients with head and neck cancer: a review. Oncologist. 2013;18:568-578.
21.
GugićJStrojanP.Squamous cell carcinoma of the head and neck in the elderly. Rep Pract Oncol Radiother. 2013;18:16-25.
22.
DahlstromKRGardenASWilliamNWJret al. Proposed staging system for patients with HPV-related oropharyngeal cancer based on nasopharyngeal cancer N categories. J Clin Oncol. 2016;34:1848-1854.
23.
AnYHolsingerFCHusainZA.De-intensification of adjuvant therapy in human papillomavirus–associated oropharyngeal cancer. Cancers of the Head and Neck. 2016;1:18.
24.
ShaikhMHMcMillanNAJohnsonNW.HPV-associated head and neck cancers in the Asia Pacific: a critical literature review and meta-analysis. Cancer Epidemiol. 2015;39:923-938.
25.
ChaturvediAKEngelsEAPfeifferRMet al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol. 2011;29:4294-4301.
26.
AminiAJonesBLMcDermottJDet al. Survival outcomes with concurrent chemoradiation for elderly patients with locally advanced head and neck cancer according to the National Cancer Data Base. Cancer. 2016;122:1533-1543.
27.
HasegawaYFukuharaTFujiwaraKet al. Treatment outcomes of head and neck squamous cell carcinoma in the elderly: a retrospective study over 7 years (2003-2009). Yonago Acta Med. 2015;58:9-13.
28.
OngWZhaoRLuiBet al. Prognostic significance of lymph node density in squamous cell carcinoma of the tongue. Head Neck. 2016;38(suppl 1):E859-E866.
29.
TanWJChiaCSTanHKSooKCIyerNG.Prognostic significance of invasion depth in oral tongue squamous cell carcinoma. ORL J Otorhinolaryngol Relat Spec. 2012;74:264-270.
30.
RolfsonORothwellASedrakyanAet al. Use of patient-reported outcomes in the context of different levels of data. J Bone Joint Surg Am. 2011;93(suppl 3):66-71.
31.
WongTHSkanthakumarTNadkarniNNguyenHVIyerNG.Survival of patients with head and neck squamous cell carcinoma by housing subsidy in a tiered public housing system. Cancer. 2017;123:1998-2005.
32.
PatelSWolffPBLinBKarnadAB.Concurrent chemotherapy plus radiation therapy (CRT) in elderly patients: a retrospective analysis. J Clin Oncol. 2010;28:15(suppl):e19660-e19660.
33.
AlongiFBignardiMGarassinoIet al. Prospective phase II trial of cetuximab plus VMAT-SIB in locally advanced head and neck squamous cell carcinoma: feasibility and tolerability in elderly and chemotherapy-ineligible patients. Strahlenther Onkol. 2012;188:49-55.
